RedHill Biopharma Ltd.

NASDAQ (USD): RedHill Biopharma Ltd. (RDHL)

Last Price

5.50

Today's Change

-0.30 (5.17%)

Day's Change

5.50 - 5.86

Trading Volume

14,266

Overview

Market Cap

7 Million

Shares Outstanding

1 Million

Avg Volume

15,900

Avg Price (50 Days)

6.68

Avg Price (200 Days)

8.93

PE Ratio

-0.02

EPS

-302.63

Earnings Announcement

13-Mar-2025

Previous Close

5.80

Open

5.82

Day's Range

5.5 - 5.8646

Year Range

5.41 - 20.275

Trading Volume

14,266

Price Change Highlight

1 Day Change

-5.17%

5 Day Change

-4.51%

1 Month Change

-12.14%

3 Month Change

-31.68%

6 Month Change

-51.54%

Ytd Change

-14.06%

1 Year Change

-58.65%

3 Year Change

-99.76%

5 Year Change

-99.89%

10 Year Change

-99.96%

Max Change

-99.94%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment